Mozafari, P. (2026) “Balancing Long-Term Efficacy and Immunological Safety: Serious Infection Risk during Extended Ocrelizumab Therapy in Multiple Sclerosis”, Junior Researchers, 4(2), pp. 57–69. doi: 10.52340/jr.2026.04.02.04.